Clinical trials
Minimal Residual Disease clinical trials
Below are recruiting minimal residual disease clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07291921Recruiting
Blood tests before and after lung cancer surgery
This study looks at changes in small molecules, genetic material, and other markers in the blood before and after lung cancer surgery. The goal is to develop a simple blood test to monitor patients over time and see if the cancer comes back.
Beijing, Beijing MunicipalityAges 18–85 - NCT07334275Recruiting
Detecting leftover cancer cells after prostate removal
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
NijmegenAges 18 years+ - NCT01311258Recruiting
Tracking leftover cancer cells in AML or high-risk MDS
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Rochester, New YorkAges 18 years+ - NCT01499394Recruiting
Biorepository study for adults who can consent
This study collects and stores samples (such as tissue or other biological materials) for future research. It mainly seeks adults who can agree to participate after understanding what it involves.
Mobile, AlabamaAges 18 years+ - NCT07660627Recruiting
ctDNA test for tracking cancer after treatment
This trial uses a blood test to find tiny bits of tumor DNA after treatment. It helps doctors see if any cancer remains, which could guide next steps for people with esophageal, stomach, or pancreatic cancer.
BrnoAges Any age - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Birmingham, AlabamaAges 19 years+ - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07524114Recruiting
Tracking cancer recurrence risk after treatment
This study uses advanced blood tests to detect tiny amounts of cancer DNA after you've completed cancer treatment. The goal is to catch any signs of cancer coming back as early as possible, which may help doctors intervene sooner.
Toronto, OntarioAges 18 years+ - NCT06694168Recruiting
Gum surgery to repair bone loss, with or without your own healing proteins
This trial tests a gum surgery technique that preserves more of your gum tissue, with or without a special protein-rich material made from your own blood (L-PRF), to repair bone loss from gum disease.
Santiago, San BernardoAges 18 years+ - NCT06428149Recruiting
Comparing gum surgery techniques for deep pockets
This study looks at three different ways to make cuts in the gums during surgery for deep pockets caused by gum disease. It aims to find which technique helps heal better and save more bone.
Murcia, MurciaAges 18–80
Hear when a new Minimal Residual Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for minimal residual disease?
- Yes. Clin2 currently lists 59 recruiting minimal residual disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a minimal residual disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a minimal residual disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.